Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series. (PubMed, Brain Dev) - Sep 22, 2026 - "Tocilizumab was associated with favorable outcomes and acceptable safety in this small pediatric series of refractory anti-NMDAR encephalitis. The CASE scale was a sensitive and reliable instrument for longitudinal functional assessment."
Journal • CNS Disorders • Dyslipidemia • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Metabolic Disorders • Pediatrics • Varicella Zoster
|
|
Andrea Del Rocio Quiroz Saavedra; Andrea G Savransky; Maria Celeste Buompadre; Maria Luz Monti; María Paula Ramos; Rocio Victoria Garcia; Silvia N Tenembaum
|